| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2010: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2008: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2007: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
|---|
| Research Abstract |
Cancer stem cell, have the ability of differentiation and self-reproduction, is important in carcinogenesis and cancer progression.
We analyzed a gene profiling between CD133 positive HuCCT1 and the CD133 negative HuCCT1 by DNA array. As a result, we were not able to find the relationship between CD133 and hepatic stem cell marker, such as CD45, TER, CD49f, and c-Met.
And then, we inoculated CD133 positive HuCCT1 and the CD133 negative HuCCT1 in the nude mouse. There was significant difference of carcinogenesis in this model. We considered that this caused in various factors, such as the cancer origin, another cancer stem cell marker except CD133.
In addition, we administered Nek2 siRNA in liver metastasis of a nude rat through portal vein using the access port. We recognized decrease of the number of the liver metastasis and the reduction of the tumor volume.
We clarified that the drug delivery system of siRNA through the portal vein was effective.
|
